State laws allowing medical cannabis use did not reduce prescriptions for opioids or other therapies for chronic, non-cancer pain, according to a policy analysis by Weill Cornell Medicine investigators.
Teva and mAbxience partner to develop biosimilar candidate for oncology
mAbxience will create oncology biosimilars using its cGMP-certified plants in Spain and Argentina. Credit: Lightspring via Shutterstock. Teva Pharmaceuticals International and mAbxience have entered into